

## **Board Resolution re PF-07321332**

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) and members of the Scientific Advisory Panel for their report assessing the final results of negotiations between MPP and PF PRIZM HOLDINGS B.V. (Pfizer) on a licence agreement (“Agreement”) for the PF-07321332 (‘332) Covid-19 antiviral. The Board has reviewed the EAG report and the proposed Agreement between MPP and Pfizer. The Board agrees with the EAG’s assessment that the proposed collaboration is consistent with the MPP’s mandate as defined in its Statutes, and that the proposed agreement represents an improvement over the status quo. The Board also takes note of the EAG’s strong recommendation for MPP to continue to work with Pfizer for an expanded Territory that would ensure access and affordability in all low- and middle-income countries.

The decision to approve the licence was reached through majority vote, following thorough discussions among Board members in view of the current political environment.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with Pfizer to formalise the collaboration, while additionally recommending that MPP continue to seek the expansion of the Territory, and urging Pfizer to work with MPP on such an expansion.